Identification of a Prognostic Clinical Score for Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Systemic Therapy Including Cetuximab

Cetuximab-based chemoimmunotherapy has been the standard of care for recurrent or metastatic squamous cell carcinoma of the head and neck (r/m SCCHN) for more than a decade. To date, no predictive or prognostic biomarkers have been established to further guide the systemic treatment with cetuximab-b...

Full description

Bibliographic Details
Published in:	Frontiers in Oncology
Main Authors:	Michael Pogorzelski, Thomas Hilser, Saskia C. Ting, Benjamin Kansy, Thomas C. Gauler, Martin Stuschke, Kurt W. Schmid, Stephan Lang, Viktor Grünwald, Martin Schuler, Stefan Kasper
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2021-05-01
Subjects:	cetuximab head and neck cancer prognostic markers predictive markers systemic treatment resistance mechanism
Online Access:	https://www.frontiersin.org/articles/10.3389/fonc.2021.635096/full

Similar Items

Early prediction of response to cetuximab and radiotherapy by FDG-PET/CT for the treatment of a locoregionally advanced squamous cell carcinoma of the hypopharynx
by: Mindaugas Grybauskas, et al.
Published: (2014-01-01)

Network meta-analysis and cost-effectiveness analysis comparing Cetuximab-β and Cetuximab for Chinese patients with RAS/BRAF wild-type metastatic colorectal cancer
by: Rongjun Tong, et al.
Published: (2025-09-01)

Lutetium 177-Labeled Cetuximab Evaluation for Radioimmunotherapeutic Applications
by: Kamal Yavari, et al.
Published: (2012-06-01)

Immune-related hepatic adverse events in renal cell carcinoma patients treated with immune checkpoint inhibitors: a retrospective study
by: Amer Saleh, et al.
Published: (2025-09-01)

Exosomes promote cetuximab resistance via the PTEN/Akt pathway in colon cancer cells
by: S. Zhang, et al.
Published: (2017-11-01)

Local ocular safety of the subconjunctival injection of cetuximab in rabbits
by: Hossein Aghaei, et al.
Published: (2023-04-01)

Cetuximab/cisplatin and radiotherapy in HNSCC: is there a favorite choice?
by: Giuliani Jacopo, et al.
Published: (2014-04-01)

Surgical resection for a huge recurrent right colon carcinoma after cetuximab plus FOLFIRI
by: Chou-Chen Chen, et al.
Published: (2021-10-01)

Formulation and evaluation of cetuximab functionalized phospholipid modified nanocrystals of paclitaxel for non-small cell lung cancer therapy
by: Manish Kumar, et al.
Published: (2024-11-01)

EBV-induced upregulation of CD55 reduces the efficacy of cetuximab treatment in nasopharyngeal carcinoma
by: Qian Zhu, et al.
Published: (2024-12-01)

The analysis of the circRNAs in the progress of acquired resistance to Cetuximab
by: Liping Yin, et al.
Published: (2022-06-01)

Panitumumab versus cetuximab in combination with irinotecan in refractory metastatic colorectal cancer
by: Maria Ignez Freitas Melro Braghiroli, et al.
Published: (2024-01-01)

Dermopathy associated with cetuximab and panitumumab: investigation of the usefulness of moisturizers in its management
by: Watanabe S, et al.
Published: (2017-09-01)

Definitive chemoradiotherapy plus cetuximab for cancer in the oesophagus or gastro-oesophageal junction
by: Gabriella Alexandersson von Döbeln, et al.
Published: (2020-01-01)

Production and evaluation of cellular effects of 153Sm-DOTA-cetuximab and 177Lu-DOTA-cetuximab radioconjugates
by: K. Yavari, et al.
Published: (2023-09-01)

Comparative effectiveness of bevacizumab, cetuximab, and panitumumab for improving outcomes in metastatic colorectal cancer: a propensity overlap weighting analysis
by: Yi-Chia Su, et al.
Published: (2025-10-01)

Nationwide pharmacovigilance data for cetuximab-induced anaphylaxis and predictive model validation using prospective specific IgE detection
by: Kyung Hee Park, et al.
Published: (2021-07-01)

miR-196b strictly regulates and reliably predicts the response to cetuximab in colorectal cancer
by: Shiyun Chen, et al.
Published: (2025-05-01)

Analysis of translesion polymerases in colorectal cancer cells following cetuximab treatment: A network perspective
by: Anubrata Das, et al.
Published: (2024-01-01)

Engineering a conditionally active cetuximab prodrug via affibody-based paratope masking
by: Anna Mestre Borras, et al.
Published: (2026-06-01)

Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers
by: Wing-Lok Chan, et al.
Published: (2014-01-01)

Treatment outcomes of cetuximab-containing regimen in locoregional recurrent and distant metastatic head and neck squamous cell carcinoma
by: Tien-Hua Chen, et al.
Published: (2022-12-01)

Effects of Cetuximab Combined with Celecoxib on Apoptosis and KDR and AQP1  Expression in Lung Cancer
by: Honggang XIA, et al.
Published: (2013-12-01)

Successful rechallenge with cetuximab after progression with nivolumab for recurrent cervical lymph node metastasis from carcinoma of the tongue
by: Yasuyuki Asada, et al.
Published: (2021-07-01)

EGFR-mediated local invasiveness and response to Cetuximab in head and neck cancer
by: Jiefu Zhou, et al.
Published: (2025-03-01)

Cetuximab Rechallenge and Monotherapy in Patients with Squamous Cell Carcinoma of the Head and Neck
by: Greg Knutzen, et al.
Published: (2015-11-01)

Evaluation of pharmacokinetics and safety of cetuximab with cisplatin/carboplatin in patients with advanced solid tumor: Result from phase II studies
by: Raymond P. Perez, et al.
Published: (2019-12-01)

Antiproliferative effects of cetuximab on triple negative breast cancer cell line MDA-MB-231
by: İdil Çetin
Published: (2020-09-01)

Engineering an Enhanced EGFR Engager: Humanization of Cetuximab for Improved Developability
by: Dennis R. Goulet, et al.
Published: (2022-01-01)

Severe drug-induced interstitial lung disease after photoimmunotherapy with cetuximab–sarotalocan sodium in a patient with oropharyngeal cancer: A case report
by: Sho Takuma, et al.
Published: (2025-01-01)

Cetuximab Enhanced the Cytotoxic Activity of Immune Cells during Treatment of Colorectal Cancer
by: Lin Wang, et al.
Published: (2017-11-01)

Clinical Observation of mXELIRI and mFOLFIRI Combined with Cetuximab in First-line Treatment of Metastatic Left-side Colon Cancer
by: CHENG Jianping, et al.
Published: (2020-07-01)

Chemotherapeutic Effectiveness of Combining Cetuximab for Metastatic Colorectal Cancer Treatment: A System Review and Meta-Analysis
by: Rong Li, et al.
Published: (2020-05-01)

Berberine: a promising strategy to combat cetuximab-resistance in colorectal cancer
by: Jianmin Ye, et al.
Published: (2025-10-01)

Cetuximab for esophageal cancer: an updated meta-analysis of randomized controlled trials
by: Ze-Hao Huang, et al.
Published: (2018-11-01)

PUM1 Is Overexpressed in Colon Cancer Cells With Acquired Resistance to Cetuximab
by: Qizhi Liu, et al.
Published: (2021-08-01)

Effect of toripalimab plus cetuximab combined with radiotherapy on patient with locally advanced high-grade parotid mucoepidermoid carcinoma
by: Yubin Wu, et al.
Published: (2025-03-01)

Cetuximab plus XELOX show efficacy against brain metastasis from colorectal cancer: a case report
by: Ahmad KH Ibrahimi, et al.
Published: (2023-06-01)

Induction chemotherapy with paclitaxel, carboplatin and cetuximab for locoregionally advanced nasopharyngeal carcinoma: A single-center, retrospective study
by: Naohiro Takeshita, et al.
Published: (2022-08-01)

In silico evaluation of the role of Fab glycosylation in cetuximab antibody dynamics
by: Simona Saporiti, et al.
Published: (2024-08-01)